

APRETUDE
(cabotegravir extended-release injectable suspension)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 12 years of age or older

Diagnosis

Patient must have the following:

1. Used for pre-exposure prophylaxis (PrEP) of HIV-1 infection
 - a. Weight \geq 35kg
 - b. Patient is at risk for sexually acquired HIV-1 infection
 - c. Patient is confirmed HIV-1 infection status negative using a test cleared by the FDA for the diagnosis of acute or primary HIV-1 infection
 - d. Apretude will be administered by a healthcare professional
 - e. Prescriber agrees to confirm the patient is HIV-1 infection status negative before each injection
 - f. Prescriber agrees to transition patient to a complete HIV-1 treatment regimen if the patient acquires HIV-1 infection during treatment with Apretude
 - g. Prescriber has counseled the patient regarding the required injection dosing schedule and the importance of adherence to scheduled dosing visits
 - h. Prescriber agrees to monitor for hypersensitivity reactions

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Same as above

Prior - Approval *Renewal* Limits

Same as above